Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08PKG
|
|||
| Former ID |
DNCL001627
|
|||
| Drug Name |
LY2541546
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Osteoporosis [ICD-11: FB83.0; ICD-10: M85.8] | Phase 2 | [1] | |
| Company |
Eli Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sclerostin (SOST) | Target Info | . | [2] |
| KEGG Pathway | Wnt signaling pathway | |||
| NetPath Pathway | TWEAK Signaling Pathway | |||
| Reactome | TCF dependent signaling in response to WNT | |||
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01144377) A Study of LY2541546 in Women With Low Bone Mineral Density. U.S. National Institutes of Health. | |||
| REF 2 | Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125(2):586-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.